Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. · 2018

Read Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. by Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6269599.txt.

Introduction

Parker and co-authors ran the STAMPEDE trial on prostate radiation in spread prostate cancer. Their trial report appeared in The Lancet. Standard care was hormone therapy for life. The trial asked whether adding radiation to the prostate itself helped men live longer. Benefit was expected to be largest in men with a low spread burden. The trial ran at 117 hospitals in the United Kingdom and Switzerland.

Over 2,000 men were assigned at random to standard care alone or with radiation. Radiation clearly lengthened the time before treatment failed. It did not lengthen overall life in the full group. Side effects were modest, with severe events in about five percent during treatment. Groups had similar rates of severe events overall. The results guide which men should get prostate radiation after spread. Subgroup tests by spread burden were built into the design.

Catalog record

CREATORParker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE65 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6269599

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial By Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P Hoyle, Adnan Ali, Alastair W S Ritchie, Gerhardt Attard, Simon Chowdhury, William Cross, David P Dearnaley, Silke Gillessen Published in: Lancet (London, England) DOI: 10.1016/S0140-6736(18)32486-3 ABSTRACT Summary Background Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy. Methods We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly allocated patients open-label in a 1:1 ratio to standard of care (control group) or standard of care and radiotherapy (radiotherapy group). Randomisation was stratified by hospital, age at randomisation, nodal involvement, WHO performance status, planned androgen deprivation therapy, planned docetaxel use (from December, 2015), and regular aspirin or non-steroidal anti-inflammatory drug use. Standard of care was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December, 2015. Men allocated radiotherapy received either a daily (55 Gy in 20 fractions over 4 weeks) or weekly (36 Gy in six fractions over 6 weeks) schedule that was nominated before randomisation. The primary outcome was overall survival, measured as the number of deaths; this analysis had 90% power with a one-sided α of 2·5% for a hazard ratio (HR) of 0·75. Secondary outcomes were failure-free survival, progression-free survival, metastatic progression-free survival, prostate cancer-specific survival, and symptomatic local event-free survival. Analyses used Cox proportional hazards and flexible parametric models, adjusted for stratification factors. The primary outcome analysis was by intention to treat. Two prespecified subgroup analyses tested the effects of prostate radiotherapy by baseline metastatic burden and radiotherapy schedule. This trial is registered with ClinicalTrials.gov, number NCT00268476. Findings Between Jan 22, 2013, and Sept 2, 2016, 2061 men underwent randomisation, 1029 were allocated the control and 1032 radiotherapy. Allocated groups were balanced, with a median age of 68 years (IQR 63–73) and median amount of prostate-specific antigen of 97 ng/mL (33–315). 367 (18%) patients received early docetaxel. 1082 (52%) participants nominated the daily radiotherapy schedule before randomisation and 979 (48%) the weekly schedule. 819 (40%) men had a low metastatic burden, 1120 (54%) had a high metastatic burden, and the metastatic burden was unknown for 122 (6%). Radiotherapy improved failure-free survival (HR 0·76, 95% CI 0·68–0·84; p<0·0001) but not overall survival (0·92, 0·80–1·06; p=0·266). Radiotherapy was well tolerated, with 48 (5%) adverse events (Radiation Therapy Oncology Group grade 3–4) reported during radiotherapy and 37 (4%) after radiotherapy. The proportion reporting at least one severe adverse event (Common Terminology Criteria for Adverse Events grade 3 or worse) was similar by treatment group in the safety population (398 [38%] with control and 380 [39%] with radiotherapy). Interpretation Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer. Funding Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis. INTRODUCTION Patients with metastatic cancer typically receive systemic treatment, with local therapy reserved—if required—for symptom palliation. However, local treatment to the primary tumour might be more useful than previously appreciated. In animal models of cancer, primary tumours metastasise not merely by disseminating tumour cells into the circulation but also by priming the premetastatic niche.1 Proliferation of tumour cells at distant sites to form overt metastases is dependent on compounds secreted by the primary tumour into the circulation.2 In these models, local treatment of the primary tumour inhibits not just the initiation of distant disease but also the progression of existing metastases. Research in contextEvidence before this studyWe searched MEDLINE (1966–2018), Embase (1982–2018), trial registers (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), and major urology and oncology conference proceedings (1990–2018) to retrieve randomised controlled trials of radiotherapy in metastatic prostate cancer. The search strategy included a range of terms to identify randomised controlled trials, prostate cancer, and radiotherapy. One relevant trial—HORRAD—was identified (n=432, 270 deaths) in which no evidence was reported of an overall survival benefit for prostate radiotherapy (hazard ratio [HR] 0·90, 95% CI 0·70–1·14), but a hypothesis was generated that survival might be improved in a subgroup of patients with low metastatic burden (HR 0·68, 95% CI 0·42–1·10).Added value of this studyTo the best of our knowledge, our large randomised trial (n=2061, 761 deaths) provides the best available evidence about the role of prostate radiotherapy in metastatic prostate cancer. Our findings showed no overall survival benefit of radiotherapy to the prostate in men with newly diagnosed prostate cancer. However, a subgroup analysis supported the hypothesis of HORRAD, that prostate radiotherapy improves survival in men with low metastatic burden.Implications of all the available evidenceEvidence suggests that prostate radiotherapy improves overall survival for men with metastatic prostate cancer who have a low metastatic burden, but not for unselected patients. Prostate radiotherapy should be a standard treatment option for men with newly diagnosed disease with a low metastatic burden. Radical local treatment of the primary tumour has been tested in several randomised controlled trials in patients with metastatic cancer. Cytoreductive nephrectomy improved survival in patients with metastatic renal carcinoma,3, 4 but this benefit was not confirmed in a more recent trial in patients with advanced disease.5 Radiotherapy to the primary tumour has not been shown to improve survival in patients with metastatic small-cell lung cancer6 or metastatic breast cancer,7 but these trials were relatively small and might not have detected a modest, but worthwhile, benefit. In men with metastatic prostate cancer, retrospective analyses have noted an association between use of radiotherapy to the primary tumour and improved overall survival.8, 9, 10, 11 The survival benefit associated with prostate radiotherapy was reported to be greater in patients with a better prognosis.8, 9, 11 The HORRAD trial randomised 432 men with metastatic prostate cancer to androgen deprivation therapy with or without prostate radiotherapy and found no evidence of an overall survival benefit (hazard ratio [HR] 0·90, 95% CI 0·70–1·14) but raised the possibility that survival might be improved in a subgroup of patients with fewer than five bone metastases (0·68, 0·42–1·10).12 We hypothesised that radical radiotherapy to the prostate would improve overall survival in men presenting with metastatic prostate cancer and that the survival benefit would be greatest in men with a low metastatic burden. METHODS Study design and participants We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had prostate cancer that was newly diagnosed, with no previous radical treatment, and had metastatic disease confirmed on a bone scintigraphic scan and soft-tissue imaging done within 12 weeks of starting androgen deprivation therapy. All patients were intended for long-term androgen deprivation therapy and started treatment no earlier than 12 weeks before randomisation. There were no age restrictions; patients were required to have no contraindications to radiotherapy and no clinically significant cardiovascular history. This trial was done in accordance with Good Clinical Practice guidelines and the

Read the complete text